Kim R S, Zaborniak C L, Begleiter A, LaBella F S
Department of Pharmacology and Therapeutics, University of Manitoba, Faculty of Medicine Winnipeg, Canada.
Cancer Lett. 1992 May 30;64(1):61-6. doi: 10.1016/0304-3835(92)90023-o.
The antiproliferative properties of three 21-aminosteroid antioxidants (lazaroids), 21-[4-[5,6-bis(diethylamino)-2-pyridinyl]-1- piperazinyl]-16 alpha-methylpregna-1,4,9(11)triene-3,20-dione, hydrochloride (U74500A), 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piper- azinyl]-pregna-1,4,9(11)-triene-3,20-dione, monomethanesulfonate (U74389F), 2H-1-benzopyran-6-ol, 2-[[4-[3-(ethylamino)-2-pyridinyl]-1-piperzinyl]methyl]-3,4- dihydro-2,5,7,8-tetramethyl-, (Z)-2-buten dioate (U78518F), on human breast cancer cells are described. U74500A inhibited cell proliferation in a dose-dependent manner with IC50 values of approximately 1.7 and 1.2 microM when cells were exposed to the drug for 3 and 5 days, respectively. The non-steroid antioxidants, alpha-tocopherol and nordihydroguaiaretic acid, showed weak or no activity at the same dose range. All three lazaroids inhibited, dose dependently, the proliferation of mouse lymphocytes but only at IC50 values ranging between 20-30 microM. The specificity of action was studied by including other steroids: progesterone, testosterone and hydrocortisone. Both sex hormones stimulated cell proliferation at low (less than 10(-5) M) concentrations but inhibited at higher doses with IC50 values of 26 (progesterone) and 80 (testosterone) microM. Hydrocortisone (IC50 0.17 microM), on the other hand, inhibited cell proliferation by 70% over a wide range of doses. Human breast cancer cells appear to have a greater sensitivity than the mouse lymphocytes to lazaroids. The antiproliferative effects of lazaroids in cancer cells may be, at least in part, due to an interaction with glucocorticoid receptors.
描述了三种21-氨基甾体抗氧化剂(拉扎罗ids),即21-[4-[5,6-双(二乙氨基)-2-吡啶基]-1-哌嗪基]-16α-甲基孕甾-1,4,9(11)三烯-3,20-二酮盐酸盐(U74500A)、21-[4-(2,6-二-1-吡咯烷基-4-嘧啶基)-1-哌嗪基]-孕甾-1,4,9(11)-三烯-3,20-二酮甲磺酸盐(U74389F)、2H-1-苯并吡喃-6-醇、2-[[4-[3-(乙氨基)-2-吡啶基]-1-哌嗪基]甲基]-3,4-二氢-2,5,7,8-四甲基-,(Z)-2-丁烯二酸酯(U78518F)对人乳腺癌细胞的抗增殖特性。当细胞分别暴露于该药物3天和5天时,U74500A以剂量依赖性方式抑制细胞增殖,IC50值分别约为1.7和1.2 microM。非甾体抗氧化剂α-生育酚和去甲二氢愈创木酸在相同剂量范围内显示出较弱或无活性。所有三种拉扎罗ids均剂量依赖性地抑制小鼠淋巴细胞的增殖,但仅在IC50值为20 - 30 microM之间。通过加入其他甾体来研究作用的特异性:孕酮、睾酮和氢化可的松。两种性激素在低浓度(小于10(-5) M)时刺激细胞增殖,但在较高剂量时抑制,IC50值分别为26(孕酮)和80(睾酮) microM。另一方面,氢化可的松(IC50 0.17 microM)在广泛的剂量范围内抑制细胞增殖达70%。人乳腺癌细胞似乎比小鼠淋巴细胞对拉扎罗ids更敏感。拉扎罗ids在癌细胞中的抗增殖作用可能至少部分归因于与糖皮质激素受体的相互作用。